Summary
Vertex Pharmaceuticals Inc. (VRTX) filed an 8-K on July 31, 2008, to report its consolidated financial results for the quarter ended June 30, 2008. The filing primarily serves as a notification that a press release detailing these results was issued on the same day. This press release, incorporated by reference as Exhibit 99.1, contains the core financial and operational updates investors would be interested in. While the 8-K itself doesn't provide the specific figures, it directs investors to the attached press release for details on Vertex's performance during the second quarter of 2008. Investors should review Exhibit 99.1 for information regarding revenue, earnings, key development milestones, and any forward-looking statements made by the company regarding its pipeline and financial outlook.
Key Highlights
- 1Vertex Pharmaceuticals Inc. reported its Q2 2008 financial results via an 8-K filing on July 31, 2008.
- 2The primary purpose of the filing is to include the press release detailing these results.
- 3The press release, Exhibit 99.1, contains the consolidated financial results for the quarter ended June 30, 2008.
- 4Investors are directed to the press release for specific financial performance data.
- 5The filing acknowledges the press release is furnished, not deemed 'filed' for Section 18 liability.
- 6Ian F. Smith, Executive Vice President and Chief Financial Officer, signed the report.